Oxford BioDynamics signs first pharma agreement for EpiSwitch Orion platform

Oxford BioDynamics has entered its first pharmaceutical partnership agreement for its proprietary EpiSwitch Orion platform, which analyzes 3D genomic architecture for precision medicine and drug development applications.

Detected & updated continuously · Source: Nebula